Table 2. Demographic, tumour and treatment characteristics of 1435 women with breast cancer by quintiles of pre-treatment platelet–lymphocyte ratio.
| Overall | Quintile 1 PLR ⩽100 n=287 | Quintile 2 100<PLR⩽129 n=287 | Quintile 3 129<PLR⩽161 n=287 | Quintile 4 161<PLR⩽215 n=287 | Quintile 5 PLR >215 n=287 | Pa | Multivariable odds ratiob (95% CI) | |
|---|---|---|---|---|---|---|---|---|
| Age (years), median | 52 | 56 | 52 | 51 | 50 | 49 | <0.001c | 1.00 (0.99–1.01) |
| Race, n (%) | <0.001c | |||||||
| Chinese | 830 (57.8) | 117 (40.8) | 150 (52.3) | 185 (64.5) | 193 (67.2) | 185 (64.5) | 1.00 | |
| Malay | 363 (25.3) | 75 (26.1) | 84 (29.3) | 69 (24.0) | 63 (22.0) | 72 (25.1) | 0.64 (0.45–0.91)c | |
| Indian | 222 (15.5) | 89 (31.0) | 49 (17.1) | 32 (11.1) | 28 (9.8) | 24 (8.4) | 0.41 (0.26–0.66)c | |
| Others | 20 (1.4) | 6 (2.1) | 4 (1.4) | 1 (0.3) | 3 (1.0) | 6 (2.1) | 1.77 (0.60–5.22) | |
| Tumour size (cm)d, median | 3.5 | 3.0 | 3.0 | 3.0 | 3.5 | 5.0 | <0.001c | 0.99 (0.95–1.03) |
| No. of positive axillary lymph nodes, n(%) | 0.091 | |||||||
| 0 | 639 (51.7) | 141 (55.1) | 148 (57.1) | 149 (55.2) | 114 (46.7) | 87 (42.2) | 1.00 | |
| 1–3 | 285 (23.1) | 57 (22.3) | 54 (20.8) | 63 (23.3) | 56 (23.0) | 55 (26.7) | 1.20 (0.82–1.75) | |
| 4–9 | 170 (13.8) | 33 (12.9) | 34 (13.1) | 29 (10.7) | 40 (16.4) | 34 (16.5) | 1.55 (0.98–2.46) | |
| ⩾10 | 141 (11.4) | 25 (9.8) | 23 (8.9) | 29 (10.7) | 34 (13.9) | 30 (14.6) | 1.74 (1.04–2.92)c | |
| Unknown | 200 | |||||||
| Distant metastasis, n (%) | <0.001c | |||||||
| None | 1222 (86.1) | 263 (92.3) | 257 (89.5) | 259 (91.5) | 242 (85.5) | 201 (71.5) | 1.00 | |
| Present | 197 (13.9) | 22 (7.7) | 30 (10.5) | 24 (8.5) | 41 (14.5) | 80 (28.5) | 1.77 (1.09–2.86)c | |
| Unknown | 16 | |||||||
| Grade, n (%) | 0.600 | |||||||
| 1 | 83 (7.7) | 21 (9.8) | 18 (8.1) | 20 (9.0) | 14 (6.4) | 10 (5.2) | 1.00 | |
| 2 | 514 (4.8) | 106 (49.3) | 106 (48.0) | 97 (43.7) | 105 (47.9) | 100 (51.5) | 1.80 (0.92–3.53) | |
| 3 | 474 (44.3) | 88 (40.9) | 97 (43.9) | 105 (47.3) | 100 (45.7) | 84 (43.3) | 1.40 (0.68–2.88) | |
| Unknown | 364 | |||||||
| Lymphovascular invasion, n (%) | 0.059 | |||||||
| None | 552 (53.4) | 124 (56.1) | 127 (58.0) | 113 (52.1) | 111 (55.0) | 77 (44.0) | 1.00 | |
| Present | 482 (46.6) | 97 (43.9) | 92 (42.0) | 104 (47.9) | 91 (45.0) | 98 (56.0) | 1.08 (0.73–1.59) | |
| Unknown | 401 | |||||||
| Oestrogen receptor status, n (%) | 0.109 | |||||||
| Negative | 612 (44.9) | 110 (40.0) | 140 (50.2) | 116 (41.6) | 124 (46.1) | 122 (46.7) | 1.00 | |
| Positive | 751 (55.1) | 165 (60.0) | 139 (49.8) | 163 (58.4) | 145 (53.9) | 139 (53.3) | 0.80 (0.53–1.19) | |
| Unknown | 72 | |||||||
| Progesterone receptor status, n (%) | 0.257 | |||||||
| Negative | 617 (51.2) | 119 (48.4) | 141 (56.2) | 119 (47.2) | 122 (51.3) | 116 (53.5) | 1.00 | |
| Positive | 587 (48.8) | 127 (51.6) | 110 (43.8) | 133 (52.8) | 116 (48.7) | 101 (46.5) | 1.30 (0.86–1.96) | |
| Unknown | 231 | |||||||
| HER2 status, n (%) | 0.007c | |||||||
| Negative | 699 (55.1) | 151 (57.9) | 151 (57.6) | 165 (63.2) | 120 (47.6) | 112 (48.3) | 1.00 | |
| Positive | 456 (36.0) | 85 (32.6) | 94 (35.9) | 78 (29.9) | 103 (40.9) | 96 (41.4) | 1.09 (0.78–1.52) | |
| Equivocal | 113 (8.9) | 25 (9.6) | 17 (6.5) | 18 (6.9) | 29 (11.5) | 24 (10.3) | 0.89 (0.50–1.60) | |
| Unknown | 167 | |||||||
| NLR (median) | 2.20 | 1.50 | 1.84 | 2.18 | 2.56 | 3.95 | <0.001c | 2.23 (1.91–2.62)c |
| Surgery, n (%) | <0.001c | — | ||||||
| None | 164 (11.4) | 24 (8.4) | 23 (8.0) | 14 (4.9) | 34 (11.8) | 69 (24.0) | ||
| Mastectomy | 989 (68.9) | 194 (67.6) | 192 (66.9) | 215 (74.9) | 209 (72.8) | 179 (62.4) | ||
| BCS | 282 (19.7) | 69 (24.0) | 72 (25.1) | 58 (20.2) | 44 (15.3) | 39 (13.6) | ||
| Radiotherapy, n (%) | 0.555 | — | ||||||
| Yes | 835 (62.3) | 169 (62.4) | 168 (61.1) | 179 (66.5) | 159 (59.8) | 160 (61.5) | ||
| None | 506 (37.7) | 102 (37.6) | 107 (38.9) | 90 (33.5) | 107 (40.2) | 100 (38.5) | ||
| Unknown | 94 | |||||||
| Neoadjuvant chemotherapy, n (%) | <0.001c | — | ||||||
| None | 1216 (84.7) | 260 (90.6) | 253 (88.2) | 254 (88.5) | 236 (82.2) | 213 (74.2) | ||
| Yes | 219 (15.3) | 27 (9.4) | 34 (11.8) | 33 (11.5) | 51 (17.8) | 74 (25.8) | ||
| Adjuvant chemotherapy, n (%) | 0.316 | - | ||||||
| None | 442 (30.8) | 103 (35.9) | 89 (31.0) | 84 (29.3) | 82 (28.7) | 84 (29.3) | ||
| Yes | 992 (69.2) | 184 (64.1) | 198 (69.0) | 203 (70.7) | 204 (71.3) | 203 (70.7) | ||
| Unknown | 1 | |||||||
| Hormone therapy, n (%) | 0.173 | — | ||||||
| None | 492 (38.1) | 92 (34.7) | 105 (40.1) | 87 (33.5) | 104 (40.9) | 104 (41.8) | ||
| Yes | 798 (61.9) | 173 (65.3) | 157 (59.9) | 173 (66.5) | 150 (59.1) | 145 (58.2) | ||
| Unknown | 145 |
Abbreviations: BCS=breast-conserving surgery; CI=confidence interval; HER2=Human epidermal growth factor receptor 2; NLR=neutrophil–lymphocyte ratio; PLR=platelet–lymphocyte ratio.
a
Derived using the χ2-test for categorical variables, and Kruskal–Wallis test for continuous variables.
b
Derived using a multivariable logistic regression model on imputed data (using cutoff for PLR=185), showing pooled odds ratios adjusted for age, race, tumour size, lymph node involvement, distant metastasis, grade, lymphovascular invasion, oestrogen receptor status, progesterone receptor status, HER2 status, and NLR.
c
Statistically significant.
d
Tumour size unknown in 86 patients.